Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> GLAXOSMITHKLINE Latest News

APR 17, 2015 - St. Louis Post-Dispatch

A Must Read - Share

Glaxo recalls flu vaccine due to potency problem

WASHINGTON (AP) — GlaxoSmithKline is recalling a popular four-in-one flu vaccine because its effectiveness can decline over time.

Tags: Glaxo recalls flu vaccine due to potency problem,  Glaxosmithkline Latest News

APR 17, 2015 - ABC News

A Must Read - Share

Glaxo Recalls Flu Vaccine Due to Potency Problem

GlaxoSmithKline recalls 1.7 million flu vaccines because they can lose potency over time

Tags: Glaxo Recalls Flu Vaccine Due to Potency Problem,  Glaxosmithkline Latest News

APR 17, 2015 - TheStreet

A Must Read - Share

Buy These 4 High-Yield Dividend Stocks to Take Advantage of the Health Care Boom

NEW YORK (TheStreet) -- The last year has been good to health-care investors. Health care stocks are up 33% over the last 12 months as measured by the Health Care Select Spider . Over the same time period, the S&P 500 has increased by about 17%. The good news is that the trends that are driving health care stocks higher ...

Tags: Buy These 4 High-Yield Dividend Stocks to Take Advantage of the Health Care Boom,  Glaxosmithkline Latest News

APR 17, 2015 - Pittsburgh Post-Gazette

A Must Read - Share

GlaxoSmithKline to shut down in Moon, leave region after 4 decades

GlaxoSmithKline will close its consumer health care operations in Moon by the end of the year, eliminating 274 jobs and ending a nearly four-decade presence in the Pittsburgh region.

Tags: GlaxoSmithKline to shut down in Moon, leave region after 4 decades,  Glaxosmithkline Latest News

APR 17, 2015 - Zacks Investment Research

A Must Read - Share

Glaxo Downgraded to Strong Sell, Delete from Your Portfolio - Analyst Blog

On Apr 15, Zacks Investment Research downgraded GlaxoSmithKline plc (GSK) to a Zacks Rank #5 (Strong Sell); delete from your portfolio.

Tags: Glaxo Downgraded to Strong Sell, Delete from Your Portfolio - Analyst Blog,  Glaxosmithkline Latest News